Nuts and Bolts of Fecal Microbiota Transplantation

Edward Krajicek, Monika Fischer, Jessica R. Allegretti, Colleen R. Kelly

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Clostridium difficile infection (CDI) has become the leading cause of nosocomial infection in the United States with significant risk of both morbidity and mortality. While antimicrobial therapy forms the basis of treatment, there are several clinical scenarios in which antimicrobial therapy alone is insufficient. Evidence continues to show the safety and efficacy fecal microbiota transplantation (FMT) in recurrent and severe CDI. This review will outline FMT efficacy, safety, and indications and present practical advice for clinicians interested in best practices around delivery of FMT.

Original languageEnglish (US)
Pages (from-to)345-352
Number of pages8
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Clostridium Infections
Clostridium difficile
Safety
Cross Infection
Practice Guidelines
Therapeutics
Morbidity
Mortality
Fecal Microbiota Transplantation

Keywords

  • Clostridium difficile
  • fecal transplant
  • FMT
  • microbiome

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Nuts and Bolts of Fecal Microbiota Transplantation. / Krajicek, Edward; Fischer, Monika; Allegretti, Jessica R.; Kelly, Colleen R.

In: Clinical Gastroenterology and Hepatology, Vol. 17, No. 2, 01.01.2019, p. 345-352.

Research output: Contribution to journalReview article

Krajicek, Edward ; Fischer, Monika ; Allegretti, Jessica R. ; Kelly, Colleen R. / Nuts and Bolts of Fecal Microbiota Transplantation. In: Clinical Gastroenterology and Hepatology. 2019 ; Vol. 17, No. 2. pp. 345-352.
@article{58fe34eb85714ff3beb515bc77ae3417,
title = "Nuts and Bolts of Fecal Microbiota Transplantation",
abstract = "Clostridium difficile infection (CDI) has become the leading cause of nosocomial infection in the United States with significant risk of both morbidity and mortality. While antimicrobial therapy forms the basis of treatment, there are several clinical scenarios in which antimicrobial therapy alone is insufficient. Evidence continues to show the safety and efficacy fecal microbiota transplantation (FMT) in recurrent and severe CDI. This review will outline FMT efficacy, safety, and indications and present practical advice for clinicians interested in best practices around delivery of FMT.",
keywords = "Clostridium difficile, fecal transplant, FMT, microbiome",
author = "Edward Krajicek and Monika Fischer and Allegretti, {Jessica R.} and Kelly, {Colleen R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cgh.2018.09.029",
language = "English (US)",
volume = "17",
pages = "345--352",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Nuts and Bolts of Fecal Microbiota Transplantation

AU - Krajicek, Edward

AU - Fischer, Monika

AU - Allegretti, Jessica R.

AU - Kelly, Colleen R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Clostridium difficile infection (CDI) has become the leading cause of nosocomial infection in the United States with significant risk of both morbidity and mortality. While antimicrobial therapy forms the basis of treatment, there are several clinical scenarios in which antimicrobial therapy alone is insufficient. Evidence continues to show the safety and efficacy fecal microbiota transplantation (FMT) in recurrent and severe CDI. This review will outline FMT efficacy, safety, and indications and present practical advice for clinicians interested in best practices around delivery of FMT.

AB - Clostridium difficile infection (CDI) has become the leading cause of nosocomial infection in the United States with significant risk of both morbidity and mortality. While antimicrobial therapy forms the basis of treatment, there are several clinical scenarios in which antimicrobial therapy alone is insufficient. Evidence continues to show the safety and efficacy fecal microbiota transplantation (FMT) in recurrent and severe CDI. This review will outline FMT efficacy, safety, and indications and present practical advice for clinicians interested in best practices around delivery of FMT.

KW - Clostridium difficile

KW - fecal transplant

KW - FMT

KW - microbiome

UR - http://www.scopus.com/inward/record.url?scp=85059172072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059172072&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2018.09.029

DO - 10.1016/j.cgh.2018.09.029

M3 - Review article

C2 - 30268564

AN - SCOPUS:85059172072

VL - 17

SP - 345

EP - 352

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 2

ER -